Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H29ClN6O3 |
Molecular Weight | 472.968 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)CN1CCN(CC2=NC(=NO2)C3=CN(CC4CCOCC4)C5=C3C=CC=C5Cl)CC1
InChI
InChIKey=AKWUNZFZIXEOPV-UHFFFAOYSA-N
InChI=1S/C23H29ClN6O3/c24-19-3-1-2-17-18(13-30(22(17)19)12-16-4-10-32-11-5-16)23-26-21(33-27-23)15-29-8-6-28(7-9-29)14-20(25)31/h1-3,13,16H,4-12,14-15H2,(H2,25,31)
Molecular Formula | C23H29ClN6O3 |
Molecular Weight | 472.968 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:46:17 GMT 2025
by
admin
on
Tue Apr 01 18:46:17 GMT 2025
|
Record UNII |
505K9LJ4MX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50648411
Created by
admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025
|
PRIMARY | |||
|
25006676
Created by
admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025
|
PRIMARY | |||
|
505K9LJ4MX
Created by
admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025
|
PRIMARY | |||
|
1050478-18-6
Created by
admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025
|
PRIMARY | |||
|
LBP-1 (drug)
Created by
admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Novel, low brain penetrant, orally bioavailable CB1 receptor agonists were designed using calculated polar surface area as a predictor of CNS permeability. This approach led to the discovery of LBP1, an orally bioavailable, low brain penetrant CB1 receptor agonist with robust activity in rodent models of neuropathic pain and a good preclinical therapeutic profile.
|